UroGen Pharma Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
UroGen Pharma Ltd. - overview
Established
2004
Location
Princeton, NJ, US
Primary Industry
Biotechnology
About
UroGen Pharma Ltd. is focused on developing and commercializing innovative therapeutics for urological cancers, particularly targeting non-muscle invasive bladder cancer with advanced treatment options. Founded in 2004 in Princeton, US, UroGen Pharma Ltd. specializes in urological cancer therapies.
The company had a significant strategic pivot towards developing FDA-approved products. Liz Barrett currently serves as CEO. UroGen completed its latest PIPE funding round in March 2022, raising USD 60. 00 mn, which equates to the total amount raised over its funding journey.
UroGen Pharma specializes in the development and commercialization of innovative therapeutics for urological cancers, focusing on non-muscle invasive bladder cancer. Their flagship product, ZUSDURI™ (mitomycin), is an FDA-approved intravesical solution for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Additionally, UroGen’s Jelmyto® (mitomycin) for pyelocalyceal solution utilizes proprietary RTGel® technology and is the first FDA-approved treatment utilizing this novel platform. These products aim to meet significant medical needs by providing effective treatment options that enhance patient quality of life.
UroGen’s customer base primarily comprises healthcare providers and institutions across the United States, where these advanced therapies are marketed and distributed. In the most recent fiscal year of 2024, UroGen Pharma generated revenue of USD 90. 40 mn. The company reported an EBITDA of USD -96.
66 mn for the same period. UroGen Pharma's revenue comes from the sale of its therapeutics, ZUSDURI™ and Jelmyto®, sold primarily to healthcare providers and specialty pharmacies in the United States. The company maintains direct-to-consumer transactions and partnerships with healthcare institutions prescribing their products for specific urological cancers. Pricing is determined based on market conditions, healthcare regulations, and reimbursement frameworks, ensuring access to transformative therapies for patients in need.
UroGen Pharma plans to leverage its recent funding from the PIPE totaling USD 60. 00 mn to support the development and launch of new therapeutic products targeting additional urological cancer indications. The company is targeting expansion into international markets, with plans to enter regions such as Europe and Asia by 2025. This growth strategy will build on their current product offerings and aims to enhance their global presence in the urological oncology space.
Current Investors
Two River, Pontifax Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.urogen.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
UroGen Pharma Ltd. - timeline of key events
UroGen Pharma Ltd. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,128,000 | 18,000 | 11,799,000 | 48,042,000 | 64,357,000 | - | - | - |
| % Revenue Growth (YoY) | - | (98.4%) | 65450.0% | 307.2% | 34.0% | - | - | - |
| EBITDA (USD) | (76,763,000) | (108,726,000) | (124,256,000) | 94,541,000 | (75,968,000) | - | - | - |
| Operating Income (USD) | (77,180,000) | (109,478,000) | (126,739,000) | 92,292,000 | (79,041,000) | - | - | - |
| Operating Margin | (6842.2%) | (608211.1%) | (1074.2%) | 192.1% | (122.8%) | - | - | - |
| % EBITDA Margin | (6805.2%) | (604033.3%) | (1053.1%) | 196.8% | (118.0%) | - | - | - |
| NET Income (USD) | (75,657,000) | (105,146,000) | (128,484,000) | 110,820,000 | (109,783,000) | - | - | - |
| % Net Margin | (6707.2%) | (584144.4%) | (1088.9%) | 230.7% | (170.6%) | - | - | - |
UroGen Pharma Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Announced | UroGen Pharma Ltd. | - |
Displaying 1 - 1 of 1
UroGen Pharma Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.